pharmaphorum4d
Novo Nordisk sheds billions in value on obesity data
and a head-to-head study pitching CagriSema against Zepbound in obesity. Novo Nordisk and Eli Lilly are currently a duopoly in the obesity market, which reached a value of $24 billion last year ...
STAT19d
Novo Nordisk’s next-generation obesity treatment shows promise in early study
LONDON — An experimental weight loss drug from Novo Nordisk helped patients shed a ... Novo as companies race to develop next-generation obesity treatments. Shares of Novo were up more than ...